ABCA7 frameshift deletion associated with Alzheimer disease in African Americans
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective: To identify a causative variant(s) that may contribute to Alzheimer disease (AD) in African Americans (AA) in the ATP-binding cassette, subfamily A (ABC1), member 7 (ABCA7) gene, a known risk factor for late-onset AD.
Methods: Custom capture sequencing was performed on ∼150 kb encompassing ABCA7 in 40 AA cases and 37 AA controls carrying the AA risk allele (rs115550680). Association testing was performed for an ABCA7 deletion identified in large AA data sets (discovery n = 1,068; replication n = 1,749) and whole exome sequencing of Caribbean Hispanic (CH) AD families.
Results: A 44-base pair deletion (rs142076058) was identified in all 77 risk genotype carriers, which shows that the deletion is in high linkage disequilibrium with the risk allele. The deletion was assessed in a large data set (531 cases and 527 controls) and, after adjustments for age, sex, and APOE status, was significantly associated with disease (p = 0.0002, odds ratio [OR] = 2.13 [95% confidence interval (CI): 1.42–3.20]). An independent data set replicated the association (447 cases and 880 controls, p = 0.0117, OR = 1.65 [95% CI: 1.12–2.44]), and joint analysis increased the significance (p = 1.414 × 10−5, OR = 1.81 [95% CI: 1.38–2.37]). The deletion is common in AA cases (15.2%) and AA controls (9.74%), but in only 0.12% of our non-Hispanic white cohort. Whole exome sequencing of multiplex, CH families identified the deletion cosegregating with disease in a large sibship. The deleted allele produces a stable, detectable RNA strand and is predicted to result in a frameshift mutation (p.Arg578Alafs) that could interfere with protein function.
Conclusions: This common ABCA7 deletion could represent an ethnic-specific pathogenic alteration in AD.
GLOSSARY
- AA=
- African Americans;
- ABC=
- ATP-binding cassette;
- AD=
- Alzheimer disease;
- CH=
- Caribbean Hispanic;
- CI=
- confidence interval;
- GATK=
- Genome Analysis Toolkit;
- GWAS=
- genome-wide association study;
- OR=
- odds ratio;
- SNV=
- single-nucleotide variant
Footnotes
↵* These authors contributed equally to the manuscript.
Coinvestigators are listed at Neurology.org/ng.
Funding information and disclosures are provided at the end of the article. Go to Neurology.org/ng for full disclosure forms. The Article Processing Charge was paid by the authors.
Supplemental data at Neurology.org/ng
- Received January 5, 2016.
- Accepted in final form March 31, 2016.
- © 2016 American Academy of Neurology
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
African American exome sequencing identifies potential risk variants at Alzheimer disease lociAurelie N'Songo, Minerva M. Carrasquillo, Xue Wang et al.Neurology: Genetics, April 07, 2017 -
Article
Rare genetic variation implicated in non-Hispanic white families with Alzheimer diseaseGary W. Beecham, Badri Vardarajan, Elizabeth Blue et al.Neurology: Genetics, November 26, 2018 -
Article
Polygenic risk scores in familial Alzheimer diseaseGiuseppe Tosto, Thomas D. Bird, Debby Tsuang et al.Neurology, February 17, 2017 -
Article
Amyloid PET Imaging in Self-Identified Non-Hispanic Black Participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) StudyKacie D. Deters, Valerio Napolioni, Reisa A. Sperling et al.Neurology, February 10, 2021